The Federal Circuit held that claim terms like “resilient” and “pliable” are not indefinite simply because they admit of varying degrees, reversing the district court’s indefiniteness ruling on a cardiac catheter patent.
The Federal Circuit applied the Supreme Court’s Minerva v. Hologic (2021) narrowed assignor estoppel framework to a medical device patent dispute, clarifying that assignor estoppel bars an inventor-assignee from challenging patent claims whose validity was implicitly warranted at assignment —
The Federal Circuit reversed a $137 million induced infringement verdict against Roche, holding that induced infringement requires actual knowledge that the induced acts constitute patent infringement, not merely a ‘knew or should have known’ standard.
The Federal Circuit reversed a claim construction that relied on extrinsic expert testimony to impose a specific frequency threshold on the term “input signal,” holding that extrinsic evidence cannot establish a claim scope limit that has no basis in the patent’s intrinsic record.
The Federal Circuit reversed the PTAB and held that Qualcomm’s 5G carrier aggregation patent was unpatentable as obvious, rejecting the Board’s motivation-to-combine analysis and addressing Intel’s standing as an Apple component supplier.
The Federal Circuit held that generic software terms like “code” and “application” can connote sufficient structure to avoid means-plus-function claiming under § 112 ¶ 6, reversing the district court’s construction.
The Federal Circuit held that in rare circumstances the Patent Trial and Appeal Board may raise grounds of unpatentability sua sponte against proposed substitute claims in a motion to amend IPR proceeding, even when a petitioner has not raised those grounds.
The Federal Circuit granted mandamus and transferred patent suits against Volkswagen and Hyundai out of the Western District of Texas, holding that independently-owned dealerships do not constitute the manufacturers’ regular and established places of business for patent venue purposes absent d
The Federal Circuit affirmed the district court’s finding of obviousness for Janssen’s patents on monthly injectable paliperidone palmitate (Invega Sustenna) for treating schizophrenia — holding that a skilled formulator would have been motivated to combine known long-acting injectable a
The Federal Circuit affirmed the PTAB’s award of CRISPR gene-editing patent rights to the Broad Institute over UC Berkeley, holding that UC’s earlier reduction to practice in prokaryotic cells did not establish a continuous conception and reduction to practice in eukaryotic cells — the m